Dulaglutide Drug Aliquot | Anti-GLP-1| Therapeutic Hormone

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Dulaglutide are now available as research consumables.

Dulaglutide drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Dulaglutide Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Trulicity® / Dulaglutide Reference Product

Drug nameTrulicity®
INNDulaglutide
API typeGlycoprotein
Pharmacotherapeutic group
Drugs used in diabetes, blood glucose lowering drugs, excl. insulins
ATC code
A10BJ05
Target of antibody
General functionDulaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as a monotherapy or in conjunction with other medicinal products for the treatment of diabetes.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. The molecule consists of 2 identical disulfide-linked chains, each containing a modified human GLP-1 analogue sequence covalently linked to a modified human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) by a small peptide linker.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Dulaglutide improves glycaemic control through the sustained effects of lowering fasting, pre-meal and postprandial glucose concentrations in patients with type 2 diabetes starting after the first dulaglutide administration and is sustained throughout the once weekly dosing interval.
Original license holder
Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands
Marketing authorisation numbers
EU/1/14/956/004
EU/1/14/956/005
EU/1/14/956/009
EU/1/14/956/010
Marketing authorisation holder
Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands
Name of the manufacturer of the biological active substance
Eli Lilly Kinsale Limited
Dunderrow
Kinsale
Co. Cork
Ireland
Name and address of the manufacturer(s) responsible for batch releaseEli Lilly Italia S.p.A.
Via Gramsci 731/733
50019, Sesto Fiorentino
Firenze (FI)
Italy

Lilly France
2, rue du Colonel Lilly
67640 Fegersheim
France
Max shelf life
2 years
Storage conditions
2°C – 8°C
List of excipients
Sodium citrate
Citric acid
Mannitol
Polysorbate 80
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting